The present review represents a translational boundary between basic research and surgery, particularly focusing on the promising application of adipose-derived stem cells harvested intra-operatively during debridement of venous leg ulcers.
Methods
We reviewed 830 out of 5578 articles on MEDLINE starting from 1997 and sorted by the relevance option.
Results
The technique currently used for adipose-derived stem cells intra-operative harvesting is presented, including a safety evaluation on a cohort of 5089 revised patients who underwent plastic surgery and maxillo-facial surgical procedures. Complications were reported in 169 cases (3.3%). One hundred and forty-one (2.77%) patients were classified as having minor complications, specifically: nodularity/induration 93 (1.83%), dysesthesia 14 (0.26%), hematoma 12 (0.23%), superficial infection 11 (0.21%), pain 7 (0.13%), poor cosmesis 3 (0.06%), and abnormal breast secretion 1 (0.02%), while 28 patients (0.55%) were classified as having major complications, specifically: deep infection 22 (0.43%), sepsis 3 (0.06%), abdominal hematoma 2 (0.04%), and pneumothorax 1 (0.02%). Application of cell therapy in venous leg ulcer is currently used only for patients not responding to the standard treatment. The review shows the lack of randomized clinical trials for application of adipose-derived stem cells among treatments for venous leg ulcer. Finally, adipose-derived stem cells implantation at the wound site promotes a new tissue formation rich in vascular structures and remodeling collagen.
Conclusion
Adipose-derived stem cells strategy represents a great opportunity for the treatment of chronic wounds, due to the simplicity of the technique and the application of cell treatment in the operating room immediately following debridement. However, clinical studies and data from randomized trials are currently lacking.
GoldmanMPWeissRABerganJJ. Diagnosis and treatment of varicose veins. A review. Dermatology1994; 31: 393–413.
2.
RobertsonLAEvansCJLeeAJ. Incidence and risk factors for venous reflux in the general population: edinburgh vein study. Eur J Vasc Endovasc Surg2014; 48: 208–214.
3.
ZamboniPGemmatiD. Clinical implications of gene polymorphisms in venous leg ulcer: a model in tissue injury and reparative process. Thromb Haemost2007; 98: 131–137.
4.
ShamiSKSarinSCheatleTR. Venous ulcers and the superficial venous system. J Vasc Surg1993; 17: 487–490.
5.
Eberth-WillershausenWMarshallM. Prevalence, risk factors and complications of peripheral venous diseases in the Munich population. Hautarzt1984; 35: 68–77.
6.
RaffettoJDMendezMVPhillipsTJ. The effect of passage number on fibroblast cellular senescence in patients with chronic venous insufficiency with and without ulcer. Am J Surg1999; 178: 107–112.
7.
RaffettoJDMendezMVMarienBJ. Changes in cellular motility and cytoskeletal actin in fibroblasts from patients with chronic venous insufficiency and in neonatal fibroblasts in the presence of chronic wound fluid. J Vasc Surg2001; 33: 1233–1241.
8.
ZamboniPCisnoCMarchettiF. Minimally invasive surgical management of primary venous ulcers vs. compression treatment: a long term randomized study. Eur J Vasc Endovasc Surg2003; 25: 313–318.
9.
GemmatiDTognazzoSCatozziL. Influence of gene polymorphisms in ulcer healing process after superficial venous surgery. J Vasc Surg2006; 44: 554–562.
10.
BarwellJRDaviesCEDeaconJ. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet2004; 363: 1854–1859.
11.
NelsonEABell-SyerSE. Compression for preventing recurrence of venous ulcers. Cochrane Database Syst Rev2014; 9: CD002303–CD002303.
12.
MauckKFAsiNElraiyahTA. Comparative systematic review and meta-analysis of compression modalities for the promotion of venous ulcer healing and reducing ulcer recurrence. J Vasc Surg2014; 60: 71S–90S.e1-2.
13.
RaffettoJD. Which dressings reduce inflammation and improve venous leg ulcer healing. Phlebology2014; 29: 157–164.
14.
ThomasCAHoldstockJMHarrisonCC. Healing rates following venous surgery for chronic venous leg ulcers in an independent specialist vein unit. Phlebology2013; 28: 132–139.
15.
GethinGCowmanSKolbachDN. Debridement for venous leg ulcers. Cochrane Database Syst Rev2015; 9: CD008599–CD008599.
16.
MauckKFAsiNUndavalliC. Systematic review and meta-analysis of surgical interventions versus conservative therapy for venous ulcers. J Vasc Surg2014; 60: 60S–70S.e1-2.
17.
LauritanoDPalmieriAVinciR. Adipose derived stem cells: basic science fundaments and clinical application. An update. Minerva Stomatol2014; 63: 273–281.
18.
De UgarteDAMorizonoKElbarbaryA. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs2003; 174: 101–109.
19.
SensebéLBourinP. Mesenchymal stem cells for therapeutic purposes. Transplantation2009; 87: S49–S53.
20.
BaglioniSFrancalanciMSqueccoR. Characterization of human adult stem-cell populations isolated from visceral and subcutaneous adipose tissue. FASEB J2009; 23: 3494–3505.
21.
HassanWUGreiserUWangW. Role of adipose-derived stem cells in wound healing. Wound Repair Regen2014; 22: 313–325.
22.
KimWSParkBSSungJH. The wound-healing and antioxidant effects of adipose-derived stem cells. Expert Opin Biol Ther2009; 9: 879–887.
BuckyLPKanchwalaSK. The role of autologous fat and alternative fillers in the aging face. Plast Reconstr Surg2007; 120: 89S–97S.
25.
MoseleyTAZhuMHedrickMH. Adipose-derived stem and progenitor cells as fillers in plastic and reconstructive surgery. Plast Reconstr Surg2006; 118: 121S–128S.
26.
ColemanSRSaboeiroAP. Fat grafting to the breast revisited: safety and efficacy. Plast Reconstr Surg2007; 119: 775–785.
GardinCBressanEFerroniL. In vitro concurrent endothelial and osteogenic commitment of adipose-derived stem cells and their genomical analyses through comparative genomic hybridization array: novel strategies to increase the successful engraftment of tissue-engineered bone grafts. Stem Cells Dev2012; 21: 767–777.
29.
KimHYJungBKLewDH. Autologous fat graft in the reconstructed breast: fat absorption rate and safety based on sonographic identification. Arch Plast Surg2014; 41: 740–747.
30.
BurnoufMBuffetMSchwarzingerM. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique. Arch Dermatol2005; 141: 1220–1224.
31.
HardyTGJoshiNKellyMH. Orbital volume augmentation with autologous micro-fat grafts. Ophthal Plast Reconstr Surg2007; 23: 445–449.
32.
DollfusCBlancheSTrocmeN. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med2009; 10: 263–268.
Guijarro-MartínezRMiragall AlbaLMarqués MateoM. Autologous fat transfer to the cranio-maxillofacial region: updates and controversies. J Craniomaxillofac Surg2011; 39: 359–363.
35.
ClaroFJrFigueiredoJCZamparAG. Applicability and safety of autologous fat for reconstruction of the breast. Br J Surg2012; 99: 768–780.
36.
GuisantesEFontdevilaJRodríguezG. Autologous fat grafting for correction of unaesthetic scars. Ann Plast Surg2012; 69: 550–554.
37.
SethAKHirschEMKimJY. Long-term outcomes following fat grafting in prosthetic breast reconstruction: a comparative analysis. Plast Reconstr Surg2012; 130: 984–990.
38.
ArcuriFBrucoliMBaragiottaN. The role of fat grafting in the treatment of posttraumatic maxillofacial deformities. Craniomaxillofac Trauma Reconstr2013; 6: 121–126.
39.
WeichmanKEBroerPNTannaN. The role of autologous fat grafting in secondary microsurgical breast reconstruction. Ann Plast Surg2013; 71: 24–30.
40.
BiglioliFAlleviFBattistaVM. Lipofilling of the atrophied lip in facial palsy patients. Minerva Stomatol2014; 63: 69–75.
41.
EndaraMRAllredLJHanKD. Applications of fat grafting in facial aesthetic skeletal surgery. Aesthet Surg J2014; 34: 363–373.
42.
KaoutzanisCXinMBallardTN. Autologous fat grafting after breast reconstruction in postmastectomy patients: complications, biopsy rates, and locoregional cancer recurrence rates. Ann Plast Surg2015. [Epub ahead of print].
MillerJPPerryEHPriceTH. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant2008; 14: 29–36.
45.
PulsipherMAChitphakdithaiPLoganBR. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood2014; 123: 3655–3663.
46.
HoltanSGWeisdorfDJ. The donor’s dilemma. Blood2014; 123: 3538–3539.
47.
UysalCATobitaMHyakusokuH. The effect of bone-marrow-derived stem cells and adipose-derived stem cells on wound contraction and epithelization. Adv Wound Care (New Rochelle)2014; 3: 405–413.
48.
Fromm-DorniedenCKoenenP. Adipose-derived stem cells in wound healing: recent results in vitro and in vivo. OA Mol Cell Biol2013; 20-1: 8–8.
49.
RizziSCUptonZBottK. Recent advances in dermal wound healing: biomedical device approaches. Expert Rev Med Devices2010; 7: 143–154.
50.
SeifterERetturaGPadawerJ. Impaired wound healing in streptozotocin diabetes. Prevention by supplemental vitamin A. Ann Surg1981; 194: 42–50.
51.
AkasakaYOnoITominagaA. Basic fibroblast growth factor in an artificial dermis promotes apoptosis and inhibits expression of alpha-smooth muscle actin, leading to reduction of wound contraction. Wound Repair Regen2007; 15: 378–389.
52.
SlavinJ. The role of cytokines in wound healing. J Pathol1996; 178: 5–10.
53.
GreenhalghDG. The role of growth factors in wound healing. J Trauma1996; 41: 59–167.
54.
HendrickxBVerdonckKVan den BergeS. Integration of blood outgrowth endothelial cells in dermal fibroblast sheets promotes full thickness wound healing. Stem Cells2010; 28: 1165–1177.
55.
CherubinoMRubinJPMiljkovicN. Adipose-derived stem cells for wound healing applications. Ann Plast Surg2011; 66: 210–215.
56.
BranskiLKGauglitzGGHerndonDN. A review of gene and stem cell therapy in cutaneous wound healing. Burns2009; 35: 171–180.
57.
NambuMKishimotoSNakamuraS. Accelerated wound healing in healing-impaired db/db mice by autologous adipose tissue-derived stromal cells combined with atelocollagen matrix. Ann Plast Surg2009; 62: 317–321.
58.
EbrahimianTGPouzouletFSquibanC. Cell therapy based on adipose tissue-derived stromal cells promotes physiological and pathological wound healing. Arterioscler Thromb Vasc Biol2009; 29: 503–510.
59.
ChoHHKyoungKMSeoMJ. Overexpression of CXCR4 increases migration and proliferation of human adipose tissue stromal cells. Stem Cells Dev2006; 15: 853–864.
60.
GimbleJMBunnellBAChiuES. Concise review: adipose-derived stromal vascular fraction cells and stem cells: let’s not get lost in translation. Stem Cells2011; 29: 749–754.
61.
GimbleJMGuilakFBunnellBA. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther2010; 1: 19–19.
62.
CervelliVDe AngelisBLucariniL. Tissue regeneration in loss of substance on the lower limbs through use of platelet-rich plasma, stem cells from adipose tissue, and hyaluronic acid. Adv Skin Wound Care2010; 23: 262–272.
63.
MarinoGMoraciMArmeniaE. Therapy with autologous adipose-derived regenerative cells for the care of chronic ulcer of lower limbs in patients with peripheral arterial disease. J Surg Res2013; 185: 36–44.
64.
BuraAPlanat-BenardVBourinP. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy2014; 16: 245–257.
65.
LeeHCAnSGLeeHW. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J2012; 76: 1750–1760.
66.
BartsichSMorrisonN. Composite fat and skin grafting for the management of chronic sickle cell ulcers. Wounds2012; 24: 51–54.
67.
MinedaKFengJIshimineH. Therapeutic potential of human adipose-derived stem/stromal cell microspheroids prepared by three-dimensional culture in non-cross-linked hyaluronic acid gel. Stem Cells Transl Med2015; 4: 1511–1522.
68.
KuoYRWangCTChengJT. Adipose-derived stem cells accelerate diabetic wound healing through the induction of autocrine and paracrine effects. Cell Transplant2016; 25: 71–81.
69.
KinoshitaKKunoSIshimineH. Therapeutic potential of adipose-derived SSEA-3-positive muse cells for treating diabetic skin ulcers. Stem Cells Transl Med2015; 4: 146–155.
70.
ShenTPanZGZhouX. Accelerated healing of diabetic wound using artificial dermis constructed with adipose stem cells and poly (L-glutamic acid)/chitosan scaffold. Chin Med J (Engl)2013; 126: 1498–1503.
71.
NieCYangDXuJ. Locally administered adipose-derived stem cells accelerate wound healing through differentiation and vasculogenesis. Cell Transplant2011; 20: 205–216.
72.
HongSJJiaSXXieP. Topically delivered adipose derived stem cells show an activated-fibroblast phenotype and enhance granulation tissue formation in skin wounds. PLoS One2013; 8: e55640–e55640.
73.
SteinbergJPHongSJGeringerMR. Equivalent effects of topically-delivered adipose-derived stem cells and dermal fibroblasts in the ischemic rabbit ear model for chronic wounds. Aesthet Surg J2012; 32: 504–519.
74.
ZografouAPapadopulosOTsigrisC. Autologous transplantation of adipose-derived stem cells enhances skin graft survival and wound healing in diabetic rats. Ann Plast Surg2013; 71: 225–232.
75.
BlantonMWHadadIJohnstoneBH. Adipose stromal cells and platelet-rich plasma therapies synergistically increase revascularization during wound healing. Plast Reconstr Surg2009; 123: 56S–64S.
76.
KimHChoiKKweonOK. Enhanced wound healing effect of canine adipose-derived mesenchymal stem cells with low-level laser therapy in athymic mice. J Dermatol Sci2012; 68: 149–156.
77.
LeeSHLeeJHChoKH. Effects of human adipose-derived stem cells on cutaneous wound healing in nude mice. Ann Dermatol2011; 23: 150–155.
78.
LimJSYooG. Effects of adipose-derived stromal cells and of their extract on wound healing in a mouse model. J Korean Med Sci2010; 25: 746–751.
79.
LinYCGrahovacTOhSJ. Evaluation of a multi-layer adipose-derived stem cell sheet in a full-thickness wound healing model. Acta Biomater2013; 9: 5243–5250.
RodriguezJBoucherFLequeuxC. Intradermal injection of human adipose-derived stem cells accelerates skin wound healing in nude mice. Stem Cell Res Ther2015; 6: 241–241.
82.
NambuMIshiharaMNakamuraS. Enhanced healing of mitomycin C-treated wounds in rats using inbred adipose tissue-derived stromal cells within an atelocollagen matrix. Wound Repair Regen2007; 15: 505–510.
83.
AmosPJKapurSKStaporPC. Human adipose-derived stromal cells accelerate diabetic wound healing: impact of cell formulation and delivery. Tissue Eng Part A2010; 16: 1595–1606.
84.
YouHJHanSKJ. Cell therapy for wound healing. Med Sci2014; 29: 311–319.
85.
AyelloEADowsettCSchultzGS. TIME heals all wounds. Nursing2004; 34: 36–41.
MessinaABortolottoSKCassellOC. Generation of a vascularized organoid using skeletal muscle as the inductive source. FASEB J2005; 19: 1570–1572.
88.
ZavanBVindigniVVezzùK. Hyaluronan based porous nano-particles enriched with growth factors for the treatment of ulcers: a placebo-controlled study. J Mater Sci Mater Med2009; 20: 235–247.
89.
PandisLZavanBAbatangeloG. Hyaluronan-based scaffold for in vivo regeneration of the rat vena cava: preliminary results in an animal model. J Biomed Mater Res A2010; 93: 1289–1296.
90.
AltmanAMYanYMatthiasN. IFATS collection: human adipose-derived stem cells seeded on a silk fibroin-chitosan scaffold enhance wound repair in a murine soft tissue injury model. Stem Cells2009; 27: 250–258.
91.
WongVWLeviBRajadasJ. Stem cell niches for skin regeneration. Int J Biomater2012; 2012: 926059–926059.
LeoneAMValgimigliMGiannicoMB. From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. Eur Heart J2009; 30: 890–899.
95.
MaengYSChoiHJKwonJY. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLCbeta2 axis. Blood2009; 113: 233–243.
96.
GemmatiDFedericiFCatozziL. DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators. J Vasc Surg2009; 50: 1444–1451.
97.
ZamboniPTognazzoSIzzoM. Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration. J Vasc Surg2005; 42: 309–314.
98.
NelsonEABell-SyerSE. Compression for preventing recurrence of venous ulcers. Cochrane Database Syst Rev2014; 9: CD002303–CD002303.
99.
O’DonnellTFJrPassmanMAMarstonWA. Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery ® and the American Venous Forum. J Vasc Surg2014; 60: 3S–59S.
100.
MostiGDe MaeseneerMCavezziA. Society for vascular surgery (SVS) and american venous forum (AVF) guidelines on management of venous leg ulcers: the International Union of Phlebology (UIP) point of view. Int Angiol2015; 34: 202–218.
101.
MonetaGL. Decreasing venous ulcers by 50% in 10 years: five critical issues in the diagnosis and investigation of venous disease. J Vasc Surg2010; 52: 44S–46S.
102.
GillespieDLWriting Group III of the Pacific Vascular Symposium 6KistnerB. Venous ulcer diagnosis, treatment, and prevention of recurrences. J Vasc Surg2010; 52: 8S–14S.
103.
MoranPSTeljeurCHarringtonP. A systematic review of intermittent pneumatic compression for critical limb ischaemia. Vasc Med2015; 20: 41–50.
104.
ManfrediniFMalagoniAMFelisattiM. Acute oxygenation changes on ischemic foot of a novel intermittent pneumatic compression device and of an existing sequential device in severe peripheral arterial disease. BMC Cardiovasc Disord2014; 31: 14:40–14:40.
105.
FerraraFMeliFRaimondiF. The treatment of venous leg ulcers: a new therapeutic use of iloprost. Ann Surg2007; 246: 860–865.
106.
Werner-SchlenzkaHKuhlmannRK. Treatment of venous leg ulcers with topical iloprost: a placebo controlled study. Vasa1994; 23: 145–150.
107.
ArosioEFerrariGSantoroL. A placebo-controlled, double-blind study of mesoglycan in the treatment of chronic venous ulcers. Eur J Vasc Endovasc Surg2001; 22: 365–372.
108.
BenjaminMMKhalilRA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS2012; 103: 209–279.
109.
MannelloFRaffettoJ. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res2011; 3: 149–158.
110.
GrinnelFZhuM. Identification of neutrophil elastase as the proteinase in burn wound fluid responsible for degradation of fibronectin. J Invest Dermatol1994; 103: 155–161.
111.
GrinnelFZhuM. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J Invest Dermatol1996; 106: 335–341.
112.
HerrickSESloanPMcGurkM. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol1992; 141: 1085–1095.
